Supplemental Digital Content 1. Disposition of study children and reasons for elimination from ATP cohort for persistence at month 66

N = 505 Total enrolled cohort for primary vaccination study

Hib-MenC-TT primed group (N = 125)
Reasons for elimination from ATP cohort:
1 wrong booster vaccine administered

MenC-TT primed group (N = 254)
Reasons for elimination from ATP cohort:
1 essential serological data missing

MenC-CRM control group (N = 126)
Reasons for elimination from ATP cohort:
5 forbidden vaccine administered

N = 184 Total enrolled cohort for persistence phase, month 18

Hib-MenC-TT primed (N = 58)
Reasons for non-participation:
4 not eligible
31 lost to follow-up
32 refused to participate, for reasons other than AE/SAE

MenC-TT primed (N = 123)
Reasons for non-participation:
6 not eligible
59 lost to follow-up
66 refused to participate, for reasons other than AE/SAE

MenC-CRM control (N = 3)*
Reasons for non-participation:
80 not eligible
19 lost to follow-up
24 refused to participate, for reasons other than AE/SAE

N = 230 Total enrolled cohort for persistence phase, month 30

Hib-MenC-TT primed (N = 54)
Reasons for non-participation:
4 not eligible
33 lost to follow-up
34 refused to participate, for reasons other than AE/SAE

MenC-TT primed (N = 119)
Reasons for non-participation:
6 not eligible
61 lost to follow-up
68 refused to participate, for reasons other than AE/SAE

MenC-CRM control (N = 57)
Reasons for non-participation:
35 lost to follow-up
34 refused to participate, for reasons other than AE/SAE

N = 220 Total enrolled cohort for persistence phase, month 42

Hib-MenC-TT primed (N = 51)
Reasons for non-participation:
4 not eligible
35 lost to follow-up
35 refused to participate, for reasons other than AE/SAE

MenC-TT primed (N = 113)
Reasons for non-participation:
7 not eligible
64 lost to follow-up
70 refused to participate, for reasons other than AE/SAE

MenC-CRM control (N = 56)
Reasons for non-participation:
36 lost to follow-up
34 refused to participate, for reasons other than AE/SAE

N = 214 Total enrolled cohort for persistence phase, month 54

Hib-MenC-TT primed (N = 50)
Reasons for non-participation:
4 not eligible
36 lost to follow-up
35 refused to participate, for reasons other than AE/SAE

MenC-TT primed (N = 108)
Reasons for non-participation:
7 not eligible
65 lost to follow-up
74 refused to participate, for reasons other than AE/SAE

MenC-CRM control (N = 56)
Reasons for non-participation:
36 lost to follow-up
34 refused to participate, for reasons other than AE/SAE

N = 205 Total enrolled cohort for persistence phase, month 66

Hib-MenC-TT primed (N = 48)
Reasons for non-participation:
4 not eligible
37 lost to follow-up
36 refused to participate, for reasons other than AE/SAE

MenC-TT primed (N = 104)
Reasons for non-participation:
7 not eligible
66 lost to follow-up
77 refused to participate, for reasons other than AE/SAE

MenC-CRM control (N = 53)
Reasons for non-participation:
36 lost to follow-up
37 refused to participate, for reasons other than AE/SAE

ATP cohort for persistence, month 66
N = 47
Reasons for elimination from ATP cohort:
1 wrong booster vaccine administered

ATP cohort for persistence, month 66
N = 103
Reasons for elimination from ATP cohort:
1 essential serological data missing

ATP cohort for persistence, month 66
N = 47
Reasons for elimination from ATP cohort:
5 forbidden vaccine administered
1 essential serological data missing

* 3 children received MenC booster vaccination but were not included in persistence analysis. Control group received additional MenC-CRM107 dose 1 month after DTPa-HBV-IPV/Hib booster outside of booster study and was excluded from M18 antibody persistence assessment. Study protocol amendment allowed antibody persistence assessment at subsequent time points.